Access & Affordability

A Bispecific Moved Earlier in Myeloma, and Brought Its Infection Risk With It

George Padron
Oncology Care, Hematologic Malignancies, Access & Affordability, Prior Authorization | Aug 2, 2026
MajesTEC-9 in NEJM found teclistamab monotherapy improved progression-free and overall survival in earlier-line myeloma, with common grade 3-4 infections.

AI for Managed Care Administration: Enhancement or Replacement? (Part 1)

George Padron
Podcasts, Healthcare Systems & Business, Digital Health & AI, Prior Authorization, Value Based Care | Jul 27, 2026
Dr. Randy Vogenberg discusses integrating AI into managed care, focusing on clinical pathways and expert guidelines.

In Standard-Risk Myeloma, Two Years of Maintenance Equals Indefinite Therapy

George Padron
Oncology Care, Hematologic Malignancies, Access & Affordability, Drug Pricing & Out-of-Pocket, Managed Care, Value Based Care | Jul 23, 2026
In standard-risk myeloma without an up-front transplant, stopping lenalidomide maintenance at 2 years matched indefinite therapy on survival, with fewer harms.

Study Finds Parkinson's Genetic Yield Varies from 0.4% to 10.7% Based on Ancestry

Sonia Reyes
Healthcare Headlines, Neurology & Mental Health, Movement Disorders, Access & Affordability, Coverage & Appeals, Managed Care, Population Health Management, Clinical Trial Updates | Jul 18, 2026
A GP2 study finds that the yield of Parkinson's gene panels varies by ancestry, and European-built panels are not transferable.

Merck's Oral PCSK9 Inhibitor Approval Undercuts Injectables

George Padron
Specialty Medicine, Healthcare Headlines, FDA & Regulations, Cardiology, Access & Affordability, Prior Authorization, Managed Care, Formulary & Coverage, Pharmacy Benefit Trends | Jul 17, 2026
FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, priced at $315 per month. Merck has positioned it below injectable options, transitioning PCSK9 medications into retail pharmacies.